Login to Your Account

Pfizer Seeks Emerging Markets, Biosimilars in Deal with Biocon

By Jennifer Boggs

Tuesday, October 19, 2010
Pfizer Inc. picked up rights to biosimilar versions of insulin in a potential $350 million-plus partnership with Indian biotech Biocon Ltd. that gives the big pharma firm access to the multibillion-dollar insulin space, as well as immediate inroads to emerging markets. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription